Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections by Mullane, Kathleen M. et al.
MAJOR ARTICLE
Efﬁcacy of Fidaxomicin Versus Vancomycin as
Therapy for Clostridium difﬁcile Infection in
Individuals Taking Concomitant Antibiotics for
Other Concurrent Infections
Kathleen M. Mullane,1 Mark A. Miller,2 Karl Weiss,3 Arnold Lentnek,4 Yoav Golan,5 Pamela S. Sears,6 Youe-Kong Shue,6
Thomas J. Louie,7 and Sherwood L. Gorbach5,6
1Department of Medicine, University of Chicago, Chicago, Illinois; 2Division of Infectious Disease, Jewish General Hospital, McGill University, Toronto,
Ontario, Canada; 3Department of Infectious Diseases and Microbiology, Maisonneuve-Rosemont Hospital, Universite ´ de Montre ´al, Montreal, Quebec,
Canada; 4Wellstar Infectious Disease, Marrietta, Georgia; 5Department of Medicine, Tufts Medical Center, Boston, Massachusetts; 6Optimer
Pharmaceuticals Inc, San Diego, California; and 7Department of Medicine, University of Calgary, Calgary, Canada
Background. Treatment guidelines recommend stopping all implicated antibiotics at the onset of Clostridium
difﬁcile infection (CDI), but many individuals have persistent or new infections necessitating the use of concomitant
antibiotics (CAs). We used data from 2 phase 3 trials to study effects of CAs on response to ﬁdaxomicin or
vancomycin.
Methods. Subjects with CDI were treated for 10 days with ﬁdaxomicin 200 mg every 12 hours or vancomycin
125 mg every 6 hours, assessed for resolution of symptoms, and followed up for an additional 4 weeks for evidence
of recurrence. Rates of cure, recurrence, and global cure (cure without recurrence) were determined for subgroups
of subjects deﬁned by CA use and treatment group.
Results. CAs were prescribed for 27.5% of subjects during study participation. The use of CAs concurrent with
CDI treatment was associated with a lower cure rate (84.4% vs 92.6%; P , .001) and an extended time to resolution of
diarrhea (97 vs 54 hours; P , .001). CA use during the follow-up was associated with more recurrences (24.8% vs
17.7%; not signiﬁcant), and CA administration at any time was associated with a lower global cure rate (65.8% vs
74.7%;P5 .005).WhensubjectsreceivedCAsconcurrentwithCDItreatment,thecureratewas90.0%forﬁdaxomicin
and 79.4% for vancomycin (P 5 .04). In subjects receiving CAs during treatment and/or follow-up, treatment with
ﬁdaxomicin compared with vancomycin was associated with 12.3% fewer recurrences (16.9% vs 29.2%; P 5 .048).
Conclusions. Treatment with CAs compromised initial response to CDI therapy and durability of response.
Fidaxomicin was signiﬁcantly more effective than vancomycin in achieving clinical cure in the presence of CA
therapy and in preventing recurrence regardless of CA use.
Antibiotic treatment is often associated with diar-
rhea and symptoms ranging from mild abdominal
discomfort to watery diarrhea, severe colitis, and even
death. Although antibiotic-associated diarrhea may
result directly from altered gastrointestinal motility or
from disruption of normal fecal ﬂora, the major cause
of antibiotic-associated diarrhea is Clostridium difﬁcile
[1–3]. C. difﬁcile is a ubiquitous, gram-positive, an-
aerobic spore-forming bacillus implicated in 20%–30%
of cases of antibiotic-associated diarrhea, in 50%–70%
of cases of antibiotic-associated colitis, and in .90% of
cases of antibiotic-associated pseudomembranous co-
litis. Asymptomatic carriage of C. difﬁcile is found in
1%–3% of healthy adults [1–3]. After recent exposure
to the hospital environment, 15%–25% of individuals
are colonized, and asymptomatic fecal carriage rates
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C.difﬁcileinfection(CDI) results fromaperfectstorm created
by disruption of the normal gut microﬂora, which forms a
protective barrier known as ‘‘colonization resistance’’ to in-
trusion of pathogenic organisms, along with overgrowth of
native or newly acquired C. difﬁcile [6–9]. Although the mech-
anisms by which antibiotics induce CDI are not clearly estab-
lished, the purported high rate of success of fecal enemas in
resolving CDI suggests that antibiotic alteration of fecal ﬂora is
an important causative factor.
The initial management of CDI involves discontinuation of
antibioticsto allow the normalbowel microﬂora torestore itself.
Although there are no controlled clinical trials demonstrating
that this improves the clinical outcome of CDI, 3 small studies
illustrated that solely discontinuing clindamycin was successful
in resolving active symptoms of CDI [10–12]. Recurrent disease,
however, was seen in 25% of cases.
Systemic infections requiring concomitant antibiotics (CAs)
often occur during the course of CDI treatment. Although
eminently logical, because antibiotics can initiate CDI, to our
knowledge, adverse effects of CAs on CDI outcomes have
heretofore not been reported. During the course of 2 phase 3
trials comparing ﬁdaxomicin, formerly OPT-80, with vanco-
mycin in 1164 CDI subjects, it was noted that more than one-
quarter of subjects received CAs for adventitious infections
during the CDI treatment period or during the immediate 4-
week follow-up. We report here the adverse effects on clinical
outcomes of CDI associated with CA therapy and the ability of
ﬁdaxomicin therapy to mitigate some of those effects in com-
parison with vancomycin treatment.
METHODS
Study Population and Design
Subjects from 2 prospective double-blinded, randomized, par-
allel-group, noninferiority studies were pooled for these analyses
(www.clinicaltrials.gov: study NCT00314951,May2006 through
August 2008, United States, Canada; study NCT00468728, April
2007 through December 2009, United States, Belgium, Canada,
France, Germany, Italy, Spain, Sweden, United Kingdom). Eli-
gible subjects were 16 years of age or older, had received a di-
agnosis of a ﬁrst episode of CDI or a ﬁrst recurrence of CDI
withintheprevious3months,andhadreceivednomorethan24
hoursofpretreatmentwithvancomycinormetronidazole(upto
4 doses). Subjects treated for $3 days with metronidazole
without improvement of symptoms were also eligible. Treat-
ment with other potentially effective therapies for CDI, eg, oral
bacitracin, fusidic acid, and rifaximin, was not allowed. CDI
was deﬁned by a change in bowel habits, with .3u n f o r m e d
bowel movements (or .200 mL unformed stool for subjects
with rectal collection devices) during the 24 hours before
randomization, and the presence of either C. difﬁcile toxin A or
B in the stool within 48 hours before randomization. Informed
consent was obtained from all study participants.
Study Conduct
Participants were randomized to receive oral ﬁdaxomicin (200
mgtwicedaily)ororalvancomycin(125mg4timesdaily)for10
days. Participants were evaluated daily during the 10-day
treatment period for cure or treatment failure on the basis of
symptoms of fever, nausea, vomiting, abdominal pain, ﬂatus,
and the number of daily bowel movements. If subjects were
cured, recurrence was assessed by means of weekly phone calls
during 4 weeks of follow-up. Fecal samples were collected
before the ﬁrst dose of study drug, at end of treatment, and
at recurrence of symptoms and assayed for toxins A and B.
All concomitant medications were recorded. Subjects were
considered to have taken CAs if they received 1 or more oral or
intravenous doses of antibiotic(s) during the treatment or
follow-up periods.
Clinical cure was deﬁned as resolution of diarrhea (#3 un-
formed stools for 2 consecutive days) maintained until the end
of therapy and for 2 days afterward. Clinical failure was deﬁned
as persistent diarrhea, the need for additional CDI therapy, or
both. Recurrence was deﬁned as the reappearance of symptoms
of CDI within 4 weeks after completing treatment, the presence
of C. difﬁcile toxin A, B, or both in stool, and the need for
retreatment. Subjects with clinical cure were followed for evi-
dence of recurrence and had an end-of-study visit between days
36 and 40. Global cure was deﬁned as clinical cure with no
recurrence. The evaluable population for cure consisted of
subjects who received $3 days of treatment and who were
considered to have experienced clinical failure and also subjects
who received $8 days of treatment and who were evaluated for
cure at an end-of-treatment visit. Subjects were evaluable for
recurrence if they were cured at the end of treatment, had re-
current symptoms within 28 days or were evaluated at a follow-
up visit 28 6 2 days following the last dose of study drug, and
received no other antibiotics for CDI and no medication that
might confound analysis of recurrence.
Antibiotics with high risk of contributing to symptomatic CDI
were identiﬁed, and CA use was also categorized by number of
classes received by each subject (Table 1; online only; [13, 14],
D. Gerding, MD, written communication, 2010; E. Goldstein,
MD, written communication, 2010; M. Miller, MD, written
communication, 2010). Topical antibiotics, treatments for CDI,
and antifungal and antiviral agents with no antibacterial activity
werenotincluded asCAs. Antineoplasticandimmunomodulating
agents were taken by 67 (11.9%) of 564 subjects in the ﬁdaxomicin
treatment group and 48 (8.2%) of 583 subjects in the vancomycin
group (safety population). Effects of these agents were not con-
sidered or controlled for in the analyses reported here.
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Study drugs were overencapsulated so that all capsules were iden-
tical in appearance. Subjects randomized to receive ﬁdaxomicin
received 2 capsules containing 125 mg ﬁdaxomicin and 2 placebo
capsules, alternating every 6 hours, each day. Subjects in the
vancomycin treatment group received 4 capsules containing 125
mg vancomycin every 6 hours each day. The investigator, sponsor,
site personnel, and subjects were blinded to treatment assignment.
Statistical Analysis
The effect of CAs used during the treatment phase (days 1–10)
was analyzed for the outcomes of clinical cure and time to
resolution of diarrhea (TTROD), and CA use at any time during
treatment and/or follow-up (days 1–40) was analyzed for global
cure. Analysis of recurrence was performed separately for CA
use during the treatment period (days 1–10), during follow-up
(days 11–40), and at any time (days 1–40). On an individual
subject basis, treatment and follow-up periods were deﬁned
by the dates of the ﬁrst and last dose of study drug and the
follow-up visit.
Response rates were determined for clinical cure, recurrence,
and global cure, and 2-sided 95% conﬁdence intervals (CIs)
were constructed around point estimates. To compare sub-
groups of subjects determined by CA exposure and CDI
Table 1. Participants Receiving Concomitant Antibiotics (CAs) by Study Period
Parameter Treatment (days 1–10)
a Treatment or follow-up (days 1–40)
Fidaxomicin
(n 5 481)
Vancomycin
(n 5 518)
All
(n 5 999)
Fidaxomicin
(n 5 481)
Vancomycin
(n 5 518)
All
(n 5 999)
Subjects evaluable for clinical
cure and global cure
No CAs used 391 (81.3) 416 (80.3) 807 (80.8) 349 (72.6) 375 (72.4) 724 (72.5)
$1 CA used 90 (18.7) 102 (19.7) 192 (19.2) 132 (27.4) 143 (27.6) 275 (27.5)
CA use by CDI risk
High
b 44 (9.1) 57 (11.0) 101 (10.1) 75 (15.6) 80 (15.4) 155 (15.5)
Medium
c 36 (7.5) 40 (7.7) 76 (7.6) 61 (12.7) 64 (12.4) 125 (12.5)
Low
d 23 (4.8) 31 (6.0) 54 (5.4) 45 (9.4) 53 (10.2) 98 (9.8)
CA use by no. of classes
e (n 5 90) (n 5 102) (n 5 192) (n 5 132) (n 5 143) (n 5 275)
1 73 (81.1) 73 (71.6) 146 (76.0) 85 (64.4) 89 (62.2) 174 (63.3)
2 13 (14.4) 25 (24.5) 38 (19.8) 31 (23.5) 39 (27.3) 70 (25.5)
3 4 (4.4) 1 (1.0) 5 (2.6) 7 (5.3) 9 (6.3) 16 (5.8)
4–6 0 3 (2.9) 3 (1.6) 9 (6.8) 6 (4.2) 15 (5.5)
Subjects evaluable for recurrence
Follow-up (days 11–40)
f Treatment or follow-up
Fidaxomicin
(n 5 391)
Vancomycin
(n 5 403)
All
(n 5 794)
Fidaxomicin
N 5 391
Vancomycin
N 5 403
All
N 5 794
No CAs used 330 (84.4) 335 (83.1) 665 (83.8) 302 (77.2) 307 (76.2) 609 (76.7)
$1 CA used 61 (15.6) 68 (16.9) 129 (16.2) 89 (22.8) 96 (23.8) 185 (23.3)
CA use by CDI risk
High
c 28 (7.2) 35 (8.7) 63 (7.9) 46 (11.8) 51 (12.7) 97 (12.2)
Medium
d 25 (6.4) 24 (6.0) 49 (6.2) 35 (9.0) 40 (9.9) 75 (9.4)
Low
e 31 (7.9) 30 (7.4) 61 (7.7) 36 (9.2) 36 (8.9) 72 (9.1)
CA use by no. of classes
f (n 5 61) (n 5 68) (n 5 129) (n 5 89) (n 5 96) (n 5 185)
1 42 (68.9) 45 (66.2) 87 (67.4) 62 (69.7) 62 (64.6) 124 (67.0)
2 11 (18.0) 16 (23.5) 27 (20.9) 17 (19.1) 25 (26.0) 42 (22.7)
3 3 (4.9) 5 (7.4) 8 (6.2) 3 (3.4) 4 (4.2) 7 (3.8)
4–6 5 (8.2) 2 (2.9) 7 (5.4) 7 (7.9) 5 (5.2) 12 (6.5)
NOTE. Data are no. (%) of subjects.
a Or from ﬁrst dose of study drug to last dose.
b Subjectreceived$1doseofhigh-riskantibiotic(carbapenem;2nd-,3rd-,or4th-generationcephalosporin,ﬂuoroquinoline,lincosamide,orpivampicillinortemocillin).
c Subject received $1 dose of medium-risk antibiotic (penicillin, penicillin combination, 1st-generation cephalosporin, macrolide, monobactam, or streptogramin).
d Subject received $1 dose of low-risk antibiotic (all other systemic antibiotics).
e There were 19 antibiotic classes (see Supplementary table). All cephalosporins were combined into 1 class, and all penicillins and penicillin combinations were
combined into 1 class.
f Or from 1 day after last dose of study drug until follow-up visit.
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and a v
2 test determined the signiﬁcance of differences in pro-
portions. TTROD was compared by means of Kaplan-Meier
analysis using log rank and Wilcoxon tests for determination of
signiﬁcance. A P value of ,.05 was considered to reveal a sig-
niﬁcant difference.
Results are presented for the per protocol population. Results
for the intent-to-treat population were similar for all outcomes.
RESULTS
Subject Population and Concomitant Antibiotic Use
A total of 1164 subjects were enrolled and 999 subjects were
evaluable for clinical and global cure (481 treated with ﬁdax-
omicin and 518 treated with vancomycin). Age of subjects
ranged from 18 to 94 years (mean 5 62 years; SD 5 18 years),
59% (584/999) were female, and 61% (606/999) were inpatients;
baseline characteristics were similar between treatment groups.
For analysis of recurrence, 794 subjects were evaluable (391
treated with ﬁdaxomicin and 403 treated with vancomycin).
Median time receiving study drug was 11 days for each treat-
ment group. Subjects who received either drug for ,8 days were
by deﬁnition those whose therapy failed after at least 3 days of
treatment.
Table 1 summarizes exposure to CAs used to treat coincident
infections by treatment period. CAs were categorized by antibiotic
class and risk of contributing to the incidence or progression of
CDI. In the combined population of 999 subjects, 275 (27.5%)
received CA(s) at some time during the study and 192 (19.2%)
received CA(s) concurrently with study drug (days 1–10).
Among the 794 subjects evaluable for analysis of recurrence
following clinical cure, 129 (16.2%) received CAs during fol-
low-up (days 11–40) and 185 subjects (23.3%) received anti-
biotics at any time during the study (days 1–40). Among
subjects who received CAs, 101 (36.7%) of 275 received .1
class of CA during study participation; 6 classes was the max-
imum taken by a single subject. Overall, 15.5% of subjects were
exposed to $1 dose of a high-risk antibiotic; 10.1% received
high-risk CAs concurrently with CDI treatment, and 7.9% of
subjects evaluable for recurrence received CAs during the fol-
low-up period. CA use was similar between the ﬁdaxomicin
and vancomycin treatment groups.
Effect of Concomitant Antibiotic Use on Clinical Outcomes
Clinical cure was achieved in 909 (91%) of 999 subjects in the
perprotocolset.For the combinedﬁdaxomicinandvancomycin
treatment groups (Table 2), clinical cure was achieved by
92.57% of subjects who did not receive CAs, compared with
84.38% of those who received CAs concurrently with study drug
(8.2% difference [95% CI, 3.0%–13.9%]; P , .001). Global cure
was observed in 74.72% of subjects who did not receive CAs but
in only 65.82% of subjects receiving CAs at any time during the
study (8.9% difference [95% CI, 2.54%–15.4%]; P 5 .005).
TTROD was lengthened by use of CAs concurrently with CDI
treatment (Figure 1). Median TTROD was 54 hours (95% CI,
51–57 hours) for subjects receiving no CAs and 97 hours (95%
CI, 58–123 hours) for those receiving CAs during the treatment
period.
Subjects who achieved clinical cure were analyzed for re-
currence within 28 days of completing treatment. Use of CAs
tended to increase recurrence but did not reach signiﬁcance
(Table 2). Antibiotic use during follow-up most inﬂuenced the
risk of recurrence: 24.81% of subjects taking CAs after com-
pleting treatment experienced recurrence within 4 weeks. In
contrast, only 17.74% of those who received no CAs after
completing treatment experienced recurrence, and the differ-
ence was marginally signiﬁcant (27.1% difference [95% CI,
215.3% to 0.60%]; P 5 .06).
Clinical cure rates were compared for subjects receiving $1
dose of 1 high-risk antibiotic and those receiving only low-risk
antibiotic(s)duringthesametimeperiod(Table3). Use ofhigh-
risk CAs decreased the rate of clinical cure by 15.48% from
96.67% to 81.19% (P 5 .04). Use of high-risk CAs tended to
increase the risk of recurrence, but the differences were not
signiﬁcant (data not shown). Overall, 101 (10%) of 999 subjects
received .1 class of antibiotic during study participation.
Table 2. Effect of Concomitant Antibiotic (CA) Therapy During Treatment and/or Follow-up Periods
Endpoint study period No CA $1 CA Difference, % (95% CI) P
Clinical cure (n 5 999)
Treatment (days 1–10) 92.57 (747/807) 84.38 (162/192) 8.19 (2.98–13.89) ,.001
Recurrence (n 5 794)
Treatment (days 1–10) 17.88 (118/660) 23.88 (32/134) 26.00 (214.04 to 1.46) .11
Follow-up (days 11–40) 17.74 (118/665) 24.81 (32/129) 27.06 (215.3 to 0.60) .06
At any time (days 1–40) 17.57 (107/609) 23.24 (43/185) 25.67 (212.63 to 0.92) .08
Global cure (n 5 999)
At any time (days 1–40) 74.72 (541/724) 65.82 (181/275) 8.91 (2.54–15.37) .005
NOTE. Data are % (proportion) of subjects unless otherwise speciﬁed.
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treatment, use of $2 classes was associated with a 71.74% cure
rate, compared with 88.36% for subjects who received #1c l a s s
(difference, 16.62% [95% CI, 230.8% to 23.24%]; P 5 .007).
There were no statistically signiﬁcant differences in recurrence
rates according to number of CA classes (data not shown).
Effect of Fidaxomicin or Vancomycin Treatment With or Without
Concomitant Antibiotics
In the absence of CA use, ﬁdaxomicin and vancomycin were
equivalent in achievement of clinical cure by the end of
treatment (92.3% vs 92.8%, respectively; P 5 .80). When sub-
jects received 1 or more CAs concurrently with study drug,
ﬁdaxomicin was superior to vancomycin in achieving clinical
cure (Table 4): 90.0% versus 79.4%, respectively (10.6% dif-
ference [95% CI, 0.23%–20.3%]; P 5 .04). When subjects re-
ceived noadditional antibiotics at anytimeduringthestudy, the
global cure rate was 80.8% for ﬁdaxomicin-treated subjects and
69.1% for vancomycin-treated subjects (11.7% difference [95%
CI, 5.43%–17.9%]; P , .001). Global cure rates were sub-
stantially reduced in both treatment groups when subjects re-
ceived CAs at any time, but signiﬁcantly more ﬁdaxomicin-
Figure 1. Kaplan-Meier analysis of time to resolution of diarrhea (TTROD). Median TTROD was 97 hours (95% confidence interval [CI], 58–123 hours)
for those who received concomitant antibiotics during the treatment period and 54 hours (95% CI, 51–57 hours) for subjects receiving no concomitant
antibiotics with treatment. The difference was significant by log rank and Wilcoxon tests (P ,.001 for each).
Table 3. Effect of Concomitant Antibiotics (CAs) by Risk and Number of Classes on Clinical Cure Rates
Clinical cure
CA use during treatment phase (days 1–10)
CA risk category
a No. of CA antibiotic classes
b
Low High 1 $2
% (proportion) of subjects 96.67 (29/30) 81.19 (82/101) 88.36 (129/146) 71.74 (33/46)
Difference (95% CI) 215.48 (21.94 to 224.39) 216.62 (230.77 to 23.24)
P .04 .007
NOTE. CI, conﬁdence interval.
a See Table 1 for explanation of risk categories. There were no signiﬁcant differences by risk category or number of classes for endpoints of recurrence and global
cure. There were no signiﬁcant differences for high risk vs low/medium risk combined for any endpoint.
b There were 19 antibiotic classes (see Supplementary table). All cephalosporins were combined into 1 class, and all penicillins and penicillin combinations were
combined into 1 class.
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with no recurrence of CDI. The proportion of subjects achieving
global cure was 72.7% for ﬁdaxomicin and 59.4% for vanco-
mycin (13.3% difference [95% CI, 2.1%–24.1%]; P 5 .02).
There was no signiﬁcant difference in TTROD between the
ﬁdaxomicin and vancomycin treatment groups in the pres-
ence or absence of CAs.
CA use increased recurrence rates for both the ﬁdaxomicin
and vancomycin treatment groups, but recurrence was consis-
tently less frequent following ﬁdaxomicin treatment whether
subjects received CAs or not (Table 4). Differences reached
signiﬁcance (P , .001) for subjects receiving no CA during
treatment, follow-up, or at any time during the study, and re-
currence was approximately doubled for all comparisons of
vancomycin with ﬁdaxomicin. For example, if subjects were
cured with ﬁdaxomicin and received no CAs during the follow-
up period, 11.5% experienced recurrence of CDI whereas 23.9%
of subjects cured with vancomycin had recurrences (difference,
212.4% [95% CI, 218.0% to 26.57%]; P , .001). Likewise, for
subjects who received CAs during follow-up after ﬁdaxomicin
cure, 21.3% had a recurrence of CDI, compared with 27.9%
of vancomycin-cured subjects (P 5 .38). When all subjects
Table 4. Comparison of Fidaxomicin and Vancomycin Treatment in the Absence or Presence of Concomitant Antibiotics (CAs)
Endpoint % (proportion) of subjects
study period Fidaxomicin Vancomycin Difference (95% CI) P
No CA
a
Clinical cure
Treatment 92.33 (361/391) 92.79 (386/416) –0.46 (–4.13 to 3.19) .80
Recurrence
Treatment 12.23 (40/327) 23.42 (78/333) 211.19 (216.89 to 25.35) ,.001
Follow-up 11.52 (38/330) 23.88 (80/335) 212.37 (218.01 to 26.57) ,.001
At any time 11.92 (36/302) 23.13 (71/307) 211.21 (217.10 to 25.16) ,.001
Global cure
At any time 80.80 (282/349) 69.07 (259/375) 11.74 (5.43–17.89) ,.001
Any CA
Clinical cure
Treatment 90.00 (81/90) 79.41 (81/102) 10.59 (0.23–20.34) .04
Recurrence
Treatment 17.19 (11/64) 30.00 (21/70) 212.81 (226.41 to 1.66) .08
Follow-up 21.31 (13/61) 27.94 (19/68) 26.63 (220.98 to 8.29) .38
At any time 16.85 (15/89) 29.17 (28/96) 212.31 (223.90 to 20.12) .048
Global Cure
At any time 72.73 (96/132) 59.44 (85/143) 13.29 (2.11–24.05) .02
No high-risk CA
b
Clinical cure
Treatment 92.22 (403/437) 91.97 (424/461) 0.25 (23.32 to 3.79) .89
Recurrence
Treatment 12.22 (44/360) 24.25 (89/367) 212.03 (217.50 to 26.42) ,.001
Follow-up 11.85 (43/363) 23.64 (87/368) 211.80 (217.20 to 26.26) ,.001
At any time 11.59 (40/345) 23.86 (84/352) 212.27 (217.79 to 26.61) ,.001
Global cure
At any time 80.79 (328/406) 68.26 (299/438) 12.52 (6.66–18.25) ,.001
Any high-risk CA
Clinical cure
Treatment 88.64 (39/44) 75.44 (43/57) 13.20 (22.25 to 27.01) .09
Recurrence
Treatment 22.58 (7/31) 27.78 (10/36) 25.20 (224.96 to 15.55) .63
Follow-up 28.57 (8/28) 34.29 (12/35) 25.71 (227.29 to 17.01) .63
At any time 23.91 (11/46) 29.41 (15/51) 25.50 (222.42 to 12.04) .54
Global cure
At any time 66.67 (50/75) 56.25 (45/80) 10.42 (24.83 to 25.11) .18
NOTE. CI, conﬁdence interval.
a See Table 1 for explanation of high risk.
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end-of-study follow-up visit were compared by treatment
group, ﬁdaxomicin had a 12.3% advantage over vancomycin
(16.9% vs 29.2%), and the difference was signiﬁcant (95% CI,
223.9% to 20.12%; P 5 .048). In subjects receiving high-risk
antibiotics, recurrence tended to be less frequent (by $5%)
following ﬁdaxomicin than vancomycin treatment, but none of
the differences was signiﬁcant.
DISCUSSION
Guidelines recommend discontinuation of CA therapy in in-
dividuals with CDI (AII recommendation [15]), but individuals
frequently require antibiotic treatment during CDI therapy to
manage concurrent systemic infections. In this study, 28% of
subjects were treated with antibiotics for other infections at the
same time as CDI treatment or during 4 weeks of follow-up.
Because subjects with immediately life-threatening CDI were
excluded from the study, this is likely an underestimate of an-
tibiotic use by all subjects treated for CDI. In this study pop-
ulation, receipt of any antibiotic concurrently with treatment
(either ﬁdaxomicin or vancomycin) reduced the cure rate from
92.6% to 84.4% (P ,.001) and prolonged the median time to
resolution by 43 hours.
Receipt of CA concurrent with vancomycin reduced the cure
rate from 92.8% overall to 79.4% (13.4% difference; P 5 .04),
but the response to ﬁdaxomicin treatment was relatively un-
affected by CA use (92.3% overall and 90.0% in the presence of
CA). We observed that treatment with antibiotics associated
with a high risk of developing CDI de novo had further negative
effects on response to therapy; however, the impact was blunted
by ﬁdaxomicin but not by vancomycin.
The risk of recurrence increased by 50% when subjects in this
study received CA(s) during the period following completion of
therapy for CDI (24.8% vs 17.8%). In a target group of subjects
who were treated successfully for CDI and who then received
CAs for another infection during the subsequent month, an es-
timate of 25% relapse may be low. In this study, a subject in
whom CA therapy was initiated on day 1 after completing CDI
treatment was followed for recurrence for 4 weeks; however
asubjectinitiatedonCAtherapyonday14aftercompletingCDI
treatment was reassessed after only 2 weeks (study day 28) and
therefore may have had a recurrence after completing the study.
Recurrence rates were consistently lower for ﬁdaxomicin-
treated subjects than for their vancomycin-treated counterparts.
Some of the protection against recurrence afforded by treatment
with ﬁdaxomicin was lost when subjects received high-risk CAs
during follow-up, supporting the model that ﬁdaxomicin spares
the commensal ﬂora and thereby reduces the risk of regrowth of
residual C. difﬁcile. Vancomycin itself can contribute to the
acquisitionofCDIandisknowntoreducefecalcountsofseveral
commensal bacterial species [16–18], so that treatment with
a second high-risk antibiotic has a lesser effect on the already
high incidence of recurrence after vancomycin treatment (99
[24.6%] of 403 overall in this study). The overall recurrence rate
following ﬁdaxomicin treatment was only 51 (13.0%) of 391 but
was more than doubled (29.0%) among subjects who received
high-risk CAs during follow-up. This is still lower than the re-
currence rate (34.3%) for subjects treated with vancomycin who
then received high-risk CAs during follow-up.
To our knowledge, response to discontinuation of antibiotics
as primary treatment of CDI has been documented in few
studies and none since the advent of widespread BI/NAP1/027
C. difﬁcile. In only 2 studies is it explicitly stated that all initial
antibiotics were stopped [19, 20]. In 3 studies, antibiotics were
discontinued unless they were deemed ‘‘essential to the patient’s
clinical treatment’’ [21, 22]. Other studies either report stopping
or switching antibiotics or make no reference to the initial an-
tibiotic [23–29].
In summary, individuals being treatedfor CDI will oftenneed
other antibiotics to treat concurrent infections, which can un-
dermine responsetotreatmentandincreasetherisk ofrelapseor
reinfection. Compared with vancomycin therapy, treatment
with ﬁdaxomicin appears to blunt the deleterious effects of
concurrent antibiotics on initial response and the risk of re-
currence.
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